Management anticipates a 30% year-over-year increase in Sequoia volumes, targeting a return on capital of approximately 20% for 2025. Aspire's expanded mandate is expected to access a $100 billion ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

A new Federal Trade Commission rule known as “click-to-cancel” targets a common frustration: the difficulty of canceling an ...